Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunshine Lake Pharma CoHKSE:06887 +3.00%15 EV-to-FCF is 126.27 as of Aug. 21, 2026, which is 51% above its 10-year median of 83.54. GuruFocus rates HKSE:06887 with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 557 Drug Manufacturers companies, Sunshine Lake Pharma Co ranks worse than 90.13% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sunshine Lake Pharma Co's Enterprise Value is HK$32,954 Mil.
Sunshine Lake Pharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$261 Mil. Therefore, Sunshine Lake Pharma Co's EV-to-FCF for today is 126.27.
The historical rank and industry rank for Sunshine Lake Pharma Co's EV-to-FCF or its related term are showing as below:
HKSE:06887'
s EV-to-FCF Range Over the Past 10 Years
Min: -43.69 Med: 83.54 Max: 126.27
Current: 126.27
During the past 4 years, the highest EV-to-FCF of Sunshine Lake Pharma Co was 126.27. The lowest was -43.69. And the median was 83.54.
HKSE:06887's EV-to-FCF is ranked worse than 90.13% of 557
companies
in the Drug Manufacturers industry
Industry Median: 20.8
vs HKSE:06887: 126.27
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sunshine Lake Pharma Co (HKSE:06887) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sunshine Lake Pharma Co's PE Ratio (TTM) for today is calculated as:
Sunshine Lake Pharma Co's share price for today is HK$38.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sunshine Lake Pharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.523.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Lake Pharma Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Lake Pharma Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sunshine Lake Pharma Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sunshine Lake Pharma Co's EV-to-FCF falls into.
Sunshine Lake Pharma Co's current Enterprise Value is HK$32,954 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sunshine Lake Pharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$261 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Lake Pharma Co (HKSE:06887) has a EV-to-FCF of 126.27 as of Aug. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sunshine Lake Pharma Co and its competitors. This is 51% above median its historical median of 83.54. According to the industry distribution chart, Sunshine Lake Pharma Co ranks #502 out of 557 companies in the Drug Manufacturers industry, placing it in the top 90.1%.
Is Sunshine Lake Pharma Co's EV-to-FCF too high?
Sunshine Lake Pharma Co's current EV-to-FCF of 126.27 is 51% above median its 10-year median of 83.54. The Drug Manufacturers industry median EV-to-FCF is 20.80. Sunshine Lake Pharma Co's value of 126.27 is 507.1% above this industry median. Based on the distribution chart, Sunshine Lake Pharma Co ranks #502 out of 557 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sunshine Lake Pharma Co has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Sunshine Lake Pharma Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sunshine Lake Pharma Co ranks #502 out of 557 companies for EV-to-FCF. This places Sunshine Lake Pharma Co in the lower half of its industry. The industry median EV-to-FCF is 20.80. Sunshine Lake Pharma Co's value of 126.27 is 507.1% above this benchmark. While the company's 10-year median is 83.54 vs. the industry median of 20.80, Sunshine Lake Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.80, based on 557 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunshine Lake Pharma Co's current EV-to-FCF of 126.27 is 507.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sunshine Lake Pharma Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Lake Pharma Co's current EV-to-FCF is 126.27, which is 51% above median its own 10-year median of 83.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Lake Pharma Co stock overvalued right now?
Sunshine Lake Pharma Co (HKSE:06887) has a current EV-to-FCF of 126.27. The current EV-to-FCF is 126.27, which is 51% above median its 10-year median of 83.54 and 507.1% above the Drug Manufacturers industry median of 20.80. Sunshine Lake Pharma Co's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sunshine Lake Pharma Co (HKSE:06887), the current EV-to-FCF is 126.27 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunshine Lake Pharma Co Ltd is a vertically integrated pharmaceutical company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. It is focused on therapeutic areas of infectious diseases, chronic diseases and oncology. The company's revenue is mainly derived from sales of pharmaceutical products to distributors in the PRC.
15GF Score
Get the complete analysis for HKSE:06887
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06887 has been successfully added to your 
